vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and Perion Network Ltd. (PERI). Click either name above to swap in a different company.
Perion Network Ltd. is the larger business by last-quarter revenue ($368.7M vs $247.1M, roughly 1.5× ANI PHARMACEUTICALS INC). ANI PHARMACEUTICALS INC runs the higher net margin — 11.1% vs 2.1%, a 9.0% gap on every dollar of revenue. ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $-2.9M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 16.4%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Perion Network Ltd. is a publicly traded advertising technology company that provides digital advertising technology solutions to advertisers, agencies, retailers, and publishers. Its core offerings are delivered through Perion One, a unified omnichannel advertising platform designed to support campaign planning, activation, optimisation, and measurement across channels and verticals including connected television (CTV), digital out-of-home (DOOH), display, video advertising, as well as retai...
ANIP vs PERI — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $368.7M |
| Net Profit | $27.5M | $7.7M |
| Gross Margin | — | — |
| Operating Margin | 14.1% | 2.0% |
| Net Margin | 11.1% | 2.1% |
| Revenue YoY | 29.6% | — |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | — | ||
| Q3 25 | $227.8M | $368.7M | ||
| Q2 25 | $211.4M | $266.5M | ||
| Q1 25 | $197.1M | $157.8M | ||
| Q4 24 | $190.6M | — | ||
| Q3 24 | $148.3M | $508.9M | ||
| Q2 24 | $138.0M | $323.6M | ||
| Q1 24 | $137.4M | $145.2M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $7.7M | ||
| Q2 25 | $8.5M | $5.6M | ||
| Q1 25 | $15.7M | $11.8M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $78.0M | ||
| Q2 24 | $-2.3M | $45.2M | ||
| Q1 24 | $18.2M | $23.8M |
| Q4 25 | 14.1% | — | ||
| Q3 25 | 15.9% | 2.0% | ||
| Q2 25 | 6.6% | -1.7% | ||
| Q1 25 | 13.3% | 5.4% | ||
| Q4 24 | -2.3% | — | ||
| Q3 24 | -13.8% | 15.1% | ||
| Q2 24 | 3.7% | 13.7% | ||
| Q1 24 | 14.8% | 16.9% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 2.1% | ||
| Q2 25 | 4.0% | 2.1% | ||
| Q1 25 | 8.0% | 7.5% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 15.3% | ||
| Q2 24 | -1.7% | 14.0% | ||
| Q1 24 | 13.2% | 16.4% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $156.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $722.9M |
| Total Assets | $1.4B | $915.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | $156.2M | ||
| Q2 25 | $217.8M | $156.2M | ||
| Q1 25 | $149.8M | $156.2M | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | $187.6M | ||
| Q2 24 | $240.1M | $187.6M | ||
| Q1 24 | $228.6M | $187.6M |
| Q4 25 | $540.7M | — | ||
| Q3 25 | $505.8M | $722.9M | ||
| Q2 25 | $436.8M | $722.9M | ||
| Q1 25 | $418.6M | $722.9M | ||
| Q4 24 | $403.7M | — | ||
| Q3 24 | $405.9M | $718.1M | ||
| Q2 24 | $455.8M | $718.1M | ||
| Q1 24 | $452.0M | $718.1M |
| Q4 25 | $1.4B | — | ||
| Q3 25 | $1.4B | $915.5M | ||
| Q2 25 | $1.3B | $915.5M | ||
| Q1 25 | $1.3B | $915.5M | ||
| Q4 24 | $1.3B | — | ||
| Q3 24 | $1.3B | $1.1B | ||
| Q2 24 | $920.8M | $1.1B | ||
| Q1 24 | $914.5M | $1.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $2.6M |
| Free Cash FlowOCF − Capex | $29.1M | $-2.9M |
| FCF MarginFCF / Revenue | 11.8% | -0.8% |
| Capex IntensityCapex / Revenue | 0.5% | 1.5% |
| Cash ConversionOCF / Net Profit | 1.10× | 0.34× |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | — | ||
| Q3 25 | $44.1M | $2.6M | ||
| Q2 25 | $75.8M | — | ||
| Q1 25 | $35.0M | — | ||
| Q4 24 | $15.9M | — | ||
| Q3 24 | $12.5M | $105.2M | ||
| Q2 24 | $17.4M | — | ||
| Q1 24 | $18.3M | $17.8M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | $-2.9M | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | $104.7M | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | $17.6M |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | -0.8% | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | 20.6% | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | 12.2% |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | 1.5% | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | 0.1% | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | 0.1% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 0.34× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.35× | ||
| Q2 24 | — | — | ||
| Q1 24 | 1.00× | 0.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PERI
| Advertising Solutions | $231.4M | 63% |
| Search Advertising | $137.3M | 37% |
